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A B S T R A C T
The dry powder inhalation of antibiotics for the treatment of lung infections has attracted
drastically increasing attention as it offers rapid local therapy at lower doses and minimal
side effects. In this study, aztreonam (AZT) was used as the model antibiotic and spray-
dried to prepare powders for inhalation. Amino acids of glycine (GLY), histidine (HIS) and
leucine (LEU) were used as excipients to modify the spray-dried particles. It was demon-
strated that the GLY-AZT spray-dried powders formed huge agglomerates with the size of
144.51 μm, which made it very difficult to be delivered to the lungs (FPF: 0.29% w/w only).
In comparison with the AZT spray-dried powders, HIS-modified spray-dried powders showed
increased compressibility, indicating larger distance and less cohesion between particles;
while the LEU-modified spray-dried particles showed a hollow structure with significantly
decreased densities.The fine particle fraction for HIS- and LEU-modified powders was 51.4%
w/w and 61.7% w/w, respectively, and both were significantly increased (one-way ANOVA,
Duncan’s test, P < 0.05) compared to that of AZT spray-dried powders (45.4% w/w), showing
a great potential to be applied in clinic.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Inhaled antibiotics attract increasing attention for the treat-
ment of lung infections, as they are directly delivered to the
local sites of infection, which therefore generate quick treat-
ment at low dose and avoid systemic side effects [1]. The
delivery of antibiotics through inhalation has developed into
a typical approach for the management of lung infections such
as chronic Pseudomonas aeruginosa associated with cystic fi-
brosis and mycobacterial pulmonary infections [2]. As a well
recognized antibiotic for the remedy of respiratory infec-
tions, aztreonam (AZT) has been formulated as inhalation
solution (Cayston®, 75 mg/dose, approved by US FDA) and is
nebulized to the lungs for the effective treatment of local in-
fections that are associated with cystic fibrosis in most cases
* Corresponding author.Testing andAnalysis Centre, Soochow University, Suzhou 215123, China.Tel.: +86 512 65880383; fax: +86 512 65880383.
E-mail address: xuying@suda.edu.cn (Y. Xu).
** Corresponding author. Suzhou Hui-Ren Biotech Co. Ltd, Suzhou 215513, China. Tel.: +86 512 51915785; fax: +86 512 51915785.
E-mail address: lihy98@hotmail.com (H.-Y. Li).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2015.08.002
1818-0876/© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 5 4 1 – 5 4 8
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
[3]. However, the use of nebulization has several drawbacks as-
sociated with its usage including inconvenience of bulk device,
low delivery efficiency and the possibility of damage to the drug
molecules by the high shear force [4,5]. In contrast, dry powder
inhalers (DPIs) are portable, easy to use and relatively cost-
effective. Additionally, rather than the use of propellent to
produce aerosols as does the pressurized metered dose inhal-
ers (pMDIs), DPIs utilize patients’ inhalation to aerosolize drug
particles and therefore avoid the coordination between the in-
halation and actuation, which may be a problem associated
with pMDIs [6]. Furthermore, the biotherapeutics of proteins,
peptides and genes may be more stable in dry state than in
aqueous solutions. DPIs therefore have become an attractive
approach for drug delivery to the lungs and have gained rapid
development in the past decades.
Spray-drying has been confirmed to be an effectual ap-
proach to prepare dry powders with sizes within the inhalable
range [7]. More importantly, spray-drying technology favors
manipulation of particles’ physiochemical properties includ-
ing particle size and size distribution, density, particle shape
and morphology [8], which may therefore enhance the powder
flowability, dispersibility and deposition in the lower respira-
tory tract during inhalation. A few studies reported that
excipient-free antibiotic (e.g. colistin) spray-dried powders
have miraculous aerosolization performance [9], and the com-
bination of different antibiotics (e.g. colistin and rifampicin)
can create spray-dried powders with multifunctional
characteristics of high delivery efficiency and moisture pro-
tection [10]. However, the excipients are usually used in
spray-drying formulations to facilitate adjustment of the
physiochemical properties of spray-dried powders in order to
enhance their dispersibility and delivery efficiency, where some
of amino acids including arginine (ARG), phenylalanine (PHE)
and leucine (LEU) have been investigated and verified as ef-
fective dispersibility enhancers. Based on their chemical
structures, the mechanism for dispersibility enhancement is
induced by the electrostatic repulsion (ARG, positively charged)
and surface modification by hydrophobic molecules (PHE and
LEU, low solubility) [11]. However, the histidine (HIS), contain-
ing the imidazol functional group, and the hydrophilic glycine
have not been investigated in terms of influencing the
physiochemical properties and subsequent aerosolization
performance of spray-dried powders. Although LEU has
been proven to be every effective in enhancing the dispersibility
of spray-dried powders, there are no data to fully disclose
the function of LEU on the AZT spray-dried powders for
inhalation.
Therefore, in this study, AZT was used as a model
drug and spray-drying was employed to prepare the dry
powders for inhalation. GLY, HIS and LEU were used as the
excipients and were dissolved in the spray-drying solution to
modify the spray-dried AZT particles.The physiochemical prop-
erties, including shape and morphology, particle size
distribution, density, moisture content, aerosolization perfor-
mance and lung deposition, were fully investigated and
compared, with the aim to generate dry powder formula-
tions that have enhanced lung delivery efficiency. This will
help further construct the links between the structure of amino
acids and the aerosolization performance of spray-dried
powders.
2. Materials and methods
2.1. Materials
AZT was bought from Shanghai Hongrui Chemical Co. Ltd
(Shanghai, China).The amino acids glycine (GLY), histidine (HIS)
and leucine (LEU) were purchased from National Medicine
Group Chemical Reagent Co. Ltd. (Shanghai, China). Potas-
sium dihydrogen phosphate and ammonia solution were
purchased from Sinopharm Chemical Reagent Co. Ltd (Shang-
hai, China). Methanol at HPLC grade was bought from Spectrum
Chemicals & Laboratory Products (Cali, USA). The capsules (3
# Gelatine) were acquired from Suzhou Capsule Company
(Suzhou, China). All other chemicals were of analytical grade
and used as received.
2.2. Preparation of spray-dried powders
AZT spray-dried powders: two grams of AZT were dissolved
in 40 mL of deionized distilled water (dd H2O) that was sub-
sequently adjusted to pH 4.5 using 1% of ammonia solution
to ensure complete drug dissolution. A laboratory scale spray
dryer (Büchi Mini Spray Dryer B-290, Büchi Labortechnik AG,
Switzerland) was used to prepare the spray-dried AZT powders
in an open-cycle system with a pressure nozzle (co-current
flow).The standard operation parameters were as follows: inlet
temperature 125 °C, aspiration rate 100%, spray flow rate 550 L/h
and pump setting 8% (2.4 mL/min). These conditions resulted
in an outlet temperature of 76–78 °C.
2.2.1. Amino acid modified spray-dried powders
The amino acids of GLY, HIS and LEU were used respectively
as the excipients to prepare spray-dried powders. For the prepa-
ration, a total mass of 2 g containing AZT and amino acid of
GLY, HIS or LEU at the mass ratio of 40:60 was dissolved in dd
H2O to prepare the spray-drying solutions that were subse-
quently spray-dried under the standard operation parameters
to prepare dry powders.After spray drying, all dry powders were
collected from the collection vessel, weighted, and stored in
vacuum desiccators for further use. Each formulation was spray-
dried in triplicate, and the spray-dried yields were reported.
2.3. Powder characterization
The morphology of spray-dried powders was visualized using
scanning electron microscope (SEM, S-5700, Hitachi Co.,Tokyo,
Japan), operated at 15 kV under high vacuum. Samples of spray-
dried powders were sputter-coated with a thin layer (~50 nm)
of gold under partial vacuum (HITACHI E-1010, Tokyo, Japan).
Representative images of the spray-dried powders were taken
under a magnification of 3000–5000×.
Laser diffraction with a dry dispersion system (Mastersizer
2000E, Malvern Instrument, Malvern, UK) was utilized to de-
termine the size distribution of dry powders. Approximately
200 mg of spray-dried powders was used to achieve the obliga-
tory obscuration of 0.5–5%, and the size distribution was
subsequently measured in triplicate for each sample. The
average particle size was expressed as the volume-weighted
mean. The particle size distribution is expressed in terms of
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the Span factor, which is calculated as (d[v, 90] − d[v, 10])/d[v,
50], where d[v, 10], d[v, 50], and d[v, 90] are the sizes in diam-
eter of a given percentage of particles smaller than the specified
size. The smaller Span represents a narrower particle size
distribution.
The weight loss of freshly prepared spray-dried powders as
a function of temperature was measured by thermogravimetric
analysis (TGA) using the Thermal Advantage TGA Q500 (TA In-
strument, USA) module.The samples (3–4 mg) were measured
in platinum pans and heated at 25–150 °C at a heating rate of
10 °C/min under nitrogen purge. Measurements were made in
triplicate.
The bulk density (ρb) and tap density (ρt) of spray-dried
powders were determined by a verified method as previously
reported with small modification [12]. The ρb of dry powders
was defined as the ratio of the powder weight over the bulk
volume, and was determined in a 1 mL of end-sealed syringe
in which a pre-determined amount of dry powders was filled.
The ρb was subsequently calculated by dividing the powder
weight by the observed bulk volume. Then, the syringe was
capped with laboratory film and tapped on a hard bench until
no change in volume of the powder was observed. The ρt was
subsequently calculated from the powder weight divided by
the tapped volume.The test was performed in triplicate for each
powder formulation. Carr’s index was derived from (1 − ρb/
ρt) × 100%, and a value less than 25% indicates a fluid powder.
2.4. Analysis of AZT
The content of AZT in the spray-dried powers was deter-
mined by high pressure liquid chromatography (HPLC).
Approximately 5 mg of spray-dried powders was dissolved into
1 mL of 0.1% ammonia solution, and subsequently vortexed
for 10 min to ensure the drug completely dissolved. A syringe
filter with a pore size of 450 nm was utilized to purify the so-
lution for the HPLC analysis of the drug contents.
The HPLC instrument, Agilent 1260 infinity, consisted of
G1312B pump, G1329B auto sampler and G1314F UV detector.
For the analysis of AZT, the drug samples (10 μL) were in-
jected into the HPLC column (5 μm C18, 250 × 4.6 mm, 80 Å,
ZORBAX Eclipse XDB, Agilent, USA) which was subsequently
eluted at a flow rate of 0.6 mL/min using a mobile phase made
up of phosphate buffer solution (pH 3 adjusted by phos-
phoric acid): methanol (70:30 v/v). AZT was detected at 263 nm.
The retention time for AZT under these conditions was 6.5 min.
The standard solutions at five different concentrations were
also used to construct the standard curve that was conse-
quently used for the analysis of the drug samples [13].
2.5. In-vitro powder aerosolization
The aerosolization performance of the spray-dried powders
from a dry powder inhaler (DPI) device was determined using
a Next Generation Impactor (NGI, Copley Scientific, Notting-
ham, UK) equipped with a USP throat and pre-separator. The
NGI is an eight-stage inertial impactor that separates the aero-
sols into isolated size ranges based on aerodynamic diameter.
For the test, the surface of NGI trays was coated with silicone
oil to prevent particle bounce.The spray-dried powders (25 mg)
were accurately weighed and loaded into size 3 gelatine
capsules, and subsequently placed into anAerolizer ® (Novartis,
Basel, Switzerland) DPI device, connected via a mouthpiece
adapter to the USP throat.The powders were subsequently aero-
solized (35% relative humidity, 20°C) at 60 L/min for 5 seconds.
Three capsules were used for each test, and the expected mass
of AZT was equivalent to 75 mg and 30 mg for AZT-only and
amino acid-modified spray-dried powders respectively. Each
powder formulation was tested in triplicate. After adminis-
tration, the capsules and inhaler device (DEV), NGI throat (THR),
pre-separator (SEP), stages 1–7 and MOCwere rinsed with water.
These solutions were subsequently filtered through a 0.45 μm
membrane, and 50 μL of the sample was employed for HPLC
analysis. For each test, the total dose (TD) was defined as the
mass of AZT loaded into the three capsules asmentioned above.
The emitted dose (ED) was defined as the mass of powder
loaded into the capsule that was released during aerosoliza-
tion, determined colorimetrically and expressed as a percentage
of TD. The recovered dose (RD) was defined as the total mass
of AZT detected after each test (i.e. capsule, inhaler, throat, pre-
separator and stages 1–7 and MOC), expressed as a percentage
of TD. The fine particle dose (FPD) was defined as the mass of
AZT detected on stage 2-MOC of the NGI (effective cut-off di-
ameter < 4.46 μm).The fine particle fraction (FPF) was calculated
as the ratio of FPD to RD, expressed as a percentage.The mass
median aerodynamic diameter (MMAD) of the powders was sub-
sequently calculated, which referred to the particle size at the
50% mark of the cumulative fraction versus the effective cut-
off diameter.
2.6. Statistical analysis
The data were statistically analyzed by the SPSS13.0 statisti-
cal software, and was presented using mean ± SD. One-way
analysis of variance (one-way ANOVA) with Duncan’s mul-
tiple comparison test was used and P < 0.05 was accepted as
significant.
3. Results and discussion
3.1. Preparation of spray-dried powders
AZT spray-dried powders, regarded as the control, showed a
yield of 80.0% w/w (Table 1). The addition of different amino
acids in the formulation generated an apparent dissimilar effect
on the spray-dried yields.The addition of GLY significantly de-
creased (one-way ANOVA, Duncan’s test, P < 0.05) the spray-
dried yield with only 29.3% w/w collected, as large amounts
of GLY-AZT spray-dried powders were observed to be ad-
sorbed on the inner surface of the spray-drying chamber and
upper section of cyclone, indicating larger particle size and
strong adhesion force for GLY-AZT spray-dried particles. The
yield for HIS-AZT spray-dried powders was 74.8% w/w that was
at the same level as that of the control.The LEU-modified spray-
dried powders showed a significantly increased (one-way
ANOVA, Duncan’s test, P < 0.05) yield of 85.2% w/w, which may
be a sign of further improvement of powder flowability, and
the reason for that might be based on the alteration of physi-
cochemical properties (e.g. particle size, density, surface
morphology and porosity) of the spray-dried particles.
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3.2. Characterization of physiochemical properties
The moisture content of spray-dried powders was deter-
mined by thermogravimetric analysis (TGA), and was estimated
from the weight loss of dry powders at temperatures of up to
150 °C (Table 1). In comparison with the moisture content
(5.52% w/w) of AZT only spray-dried powders, the amino acid-
modified spray-dried powders showed a significantly decreased
(one-way ANOVA, Duncan’s test, P < 0.05) moisture content in
the range of 2.45–4.50% w/w, suggesting amino acid can di-
minish the water content in the spray-dried powders. The
decrease of moisture content in the spray-dried powders is po-
tentially supportive to improve the flowability and further
enhance the lung deposition.
It was demonstrated that the ρb and ρt for AZT spray-
dried powders were 0.40 and 0.58 g/cm3 respectively (Table 1).
The addition of GLY into the formulation significantly in-
creased (One-way ANOVA, Duncan’s test, P < 0.05) the ρb (0.72 g/
cm3) and ρt (0.80 g/cm3), suggesting that they were dense
particles. In comparison with the control powders, the HIS-
AZT spray-dried powders had a similar ρb of 0.49 g/cm3, and
significantly higher (one-way ANOVA, Duncan’s test, P < 0.05)
ρt of 0.79 g/cm3, suggesting a better compressibility and a bigger
distance between particles, further indicating less cohesion
between particles and better dispersibility. Interestingly, the LEU-
AZT spray-dried powders demonstrated a very low ρb and ρt
of 0.17 g/cm3 and 0.28 g/cm3 respectively, significantly reduced
(one-way ANOVA, Duncan’s test, P < 0.05) than those of control
powders. Carr’s Index value is an indication of free flowing
powders; a value less than 25% indicates a fluid flowing powder,
whereas a value greater than 25% indicates cohesive powder
characteristics. Carr’s index values for AZT, HIS-AZT and LEU-
AZT spray-dried powders were 30.8%, 37.6% and 38.3%
respectively, affirming poor flowability for these dry powders.
The GLY-AZT dry powders had a Carr’s index value of 9.8%,
stating good flowability. However, there was no relationship ob-
served between particle size and the representative Carr’s index
values.
The surface morphology of spray-dried powders was visu-
alized by scanning electron microscopy (Fig. 1). The surface
morphology of AZT only spray-dried powders had a wrinkled
surface with high roughness (Fig. 1A). All amino acids, added
Table 1 – Physiochemical properties of LEU-modified spray-dried AZT powders. The data were expressed as the
mean ± SD.
Spray dried
powders
Yield (w/w %) ρb (g/cm3) ρt (g/cm3) Carr’s
index (%)
Moisture
content (w/w %)
AZT 80.0 (1.6) 0.40 (0.11) 0.58 (0.11) 30.8 (4.7) 5.52 (0.20)
GLY-AZT 29.3 (7.0)‡ 0.72 (0.01)† 0.80 (0.02)† 9.8 (1.4)‡ 2.45 (0.17)‡
HIS-AZT 74.8 (7.6) 0.49 (0.02) 0.79 (0.01)† 37.6 (2.4) 4.50 (0.25)‡
LEU-AZT 85.2 (2.2)† 0.17 (0.01)‡ 0.28 (0.01)‡ 38.3 (1.9) 3.34 (0.04)‡
The data with ‘†’ and ‘‡’ indicate significant increase and decrease (one-way ANOVA, Duncan’s test, P < 0.05), respectively, in comparison with
the control.
A
D
B
C
Fig. 1 – The size and morphology of spray-dried powders visualized by SEM. A: AZT; B: GLY-AZT; C: HIS-AZT; D: LEU-AZT.
Bar = 10 μm.
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into the spray-drying solution, can drastically change the par-
ticle morphology. The GLY-AZT spray-dried particles formed
aggregates that were bigger than 10 μm, strongly suggesting
a poor aerosolization performance and lower deposition in the
lungs (Fig. 1B). The HIS-AZT spray-dried particles showed a
sphere-like shape with a relatively smooth and slightly wrinkled
surface, comparable to those of AZT spray-dried particles. LEU,
added into the formulation, can greatly change the surface mor-
phology and structure of the spray-dried particles. The LEU-
AZT spray-dried particles showed broken surfaces with hollow
structure inside, indicative of decreased density of dry powders
and hence improved aerosolization performance. All spray-
dried particles of AZT, HIS-AZT and LEU-AZT showed the size
less than 10 μm, which could potentially be inhaled into the
lower respiratory tract.
Laser diffraction was utilized to determine the particle size
distribution of spray-dried powders (Fig. 2).The AZT only spray-
dried powders showed size distribution of less than 10 μm
(Fig. 2A). Although the GLY-AZT spray-dried powders showed
a unimodal size distribution, the particle size was very large,
up to ~1000 μm (Fig. 2B), while the HIS- and LEU-modified spray-
dried powders showed size distributions less than 10 μm (Fig. 2C
and D). All these data were in good agreement to the particle
size observed under SEM. In order to further elucidate the par-
ticle size distribution, the mean diameter over the volume
distribution D [4, 3] and the Span were reported (Table 2). The
AZT, HIS-AZT and LEU-AZT had a mean diameter of 2.15–
2.31 μm, providing further evidence that they can be delivered
to the lower respiratory tract. Additionally, the LEU-AZT had
the smallest Span of 1.32, suggesting a narrowest size distri-
bution and further indicating a superior uniform particle size,
in comparison withAZT and HIS-AZT spray-dried powders. Con-
versely, the GLY-AZT spray-dried powders showed a larger mean
diameter of 144.51 μm, with a Span of 2.07, which is ex-
pected to have a very poor drug deposition in the lower
respiratory tract through inhalation.
The primary aerodynamic diameter (dae) was theoretically es-
timated from the particle sizing (d) and tapped density by the
formulaofdae = d (ρt/ρ1)1/2,whereρ1 = 1 g/cm3.Theexposedprimary
particle diameterwas 1.65 μmforAZT spray-dried powders.The
dae was significantly large (129.26 μm) for GLY-AZT spray-dried
powders, which was far beyond the size range for inhalation.
The HIS- and LEU-modified spray-dried powders had a dae of
1.91 μm and 1.22 μm respectively; the lower dae of the LEU-
modifiedpowders suggests that the formulation couldpotentially
have higher dispersibility and could have an improved depo-
sition in the lungs. For any single dry powder formulation, the
dae was smaller than the particle size determined by laser dif-
fraction (D [4, 3]), suggesting the powders formed aggregates in
the airflow during the laser diffraction test [14].
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Fig. 2 – Particle size distribution of AZT spray-dried powders determined by laser diffraction. A: AZT; B: GLY-AZT; C: HIS-
AZT; D: LEU-AZT.
Table 2 – Particle size distribution of spray-dried powders. The powders were tested in dry state, and the laser diffraction
was utilized to determine the particle size distribution (data expressed as mean ± SD).
Spray dried
powders
d[v, 10] (μm) d[v, 50] (μm) d[v, 90] (μm) Span D [4, 3] (μm) dae (μm)
AZT 0.55 (0.11) 2.11 (0.02) 3.72 (0.09) 1.53 (0.10) 2.17 (0.02) 1.65 (0.19)
GLY-AZT 36.58 (0.51) 120.94 (0.95) 286.93 (1.33) 2.07 (0.02) 144.51 (0.82) 129.26 (1.90)
HIS-AZT 0.62 (0.09) 2.09 (0.03) 3.69 (0.08) 1.47 (0.09) 2.15 (0.02) 1.91 (0.02)
LEU-AZT 1.06 (0.02) 2.15 (0.15) 3.89 (0.03) 1.32 (0.09) 2.31 (0.03) 1.22 (0.02)
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3.3. In-vitro aerosolization and deposition
Next Generation Impactor (NGI) was employed to determine
the in-vitro aerosolization and deposition of the spray-dried
powders. For the test, Aerolizer® was utilized to aerosolize the
dry powders where the amount of dry powders emitted from
the capsules is expressed as a parameter of ED, which will
reflect the influence of amino acids on the flowability of spray-
dried powders. ForAZT only spray-dried powders, approximately
85.6 ± 1.6% was emitted from the capsules during the aero-
solization. The ED for GLY-AZT spray-dried powders was
100 ± 0.0%, suggesting all powders were emitted from the cap-
sules, and further indicating GLY-AZT spray-dried powders had
flowability, which was in agreement with the data of Carr’s
index value.The spray-dried powders modified by HIS and LEU
had EDs of 92.8 ± 0.7% and 98.0 ± 0.7% respectively, suggest-
ing LEUwasmore effective than HIS in improving the flowability
of spray-dried powders. Many reports have demonstrated that
the use of LEU, either through coating on the particle surface,
adding to the solution for spray-dried powders, or physically
mixing with drug particles, can dramatically improve the
flowability of drug particles [12,15–17]. Additionally, our pre-
vious paper has demonstrated that other amino acids such as
arginine, phenylalanine and threonine can also improve the
flowability of spray-dried powders [11]. In this paper, we further
confirmed that use of amino acids did work well to improve
aerosolization performance of spray-dried powders, and may
further enhance the drug deposition in the lungs.
Undoubtedly, ED is a compulsory characteristic of feasible
dry powder inhaler systems; however, the more crucial feature
is the deposition site of drug particles in the respiratory tract
once emitted from the inhaler. NGI has been well recognized
as a device to test the in vitro lung deposition of inhaled par-
ticles, based on their aerodynamic size distribution [18], and
it has been used as a standardmethod for the testing of inhaled
products in the pharmacopeia of Europe, USA and other coun-
tries. The deposition pattern of spray-dried AZT alone
demonstrated that a large amount of the powders remained
in the device and capsules following aerosolization, and that
a large proportion of the powder was deposited in the throat
(Fig. 3). A certain amount of drug particles can flow into lower
stages and was mainly deposited in stages 2 and 3. All amino
acid-modified spray-dried powders had a significantly de-
creased (one-way ANOVA, Duncan’s test, P < 0.05) amount of
drug that remained in the capsules and device, clearly exhib-
iting an improved aerosolization performance over the AZT
powder. However, over 90%w/w of GLY-AZT spray-dried powders
were deposited in the throat and pre-separator, with smaller
proportion of the powders depositing on to the lower stages,
suggesting that the inhalation of AZT powder would result in
a significant deposition in the oropharyngeal region and the
upper bronchi. Clearly, GLY-AZT spray-dried powders were un-
suitable for the drug delivery to the lungs. On the other hand,
the HIS-AZT spray-dried powders showed a significant in-
crease of deposition in stage 2 (cut-off diameter of 4.46 μm) over
the control, indicating that the inhalation of HIS-AZT would
generate an improved deposition in the lower respiratory tract.
However, the LEU-modified spray-dried powders had a signifi-
cant reduction of deposition in the throat, indicating that the
powder had an improved dispersibility. As expected, the
LEU-AZT powder had an improved deposition in the lower
stages. The drug deposition on stage 2 was significantly in-
creased for LEU-AZT, with more than two times that of the
control powder. Additionally, the total percentage of drug de-
position on stage 5 to MOC (cut-off diameter < 0.94 μm) was
26.2% for LEU-AZT powder, while only 13.7% was found for the
control powder. Clearly, following inhalation, the LEU-modified
powders would generate minimal deposition in the upper
airways with a larger proportion of the dry powders flowing
into the lower respiratory tract, and the deposition in the al-
veolar regions would be highly enhanced.
For AZT spray-dried powders, the TD in each aerosoliza-
tion test was 75 mg (25 mg powder per capsule, three capsules
per test).The powder exhibited a FPD of 24.7 mg of AZT (Table 3),
and the FPF of spray-dried powder was 45.4% of the total re-
covered drug contents (54.4 mg).The reason could be attributed
to the morphology of AZT microparticles that have decreased
surface contact, therefore reducing the interaction forces
between particles, and improving flowability, dispersibility, and
aerosolization performance [19]. As expected, the GLY-AZT
spray-dried powders, with huge particle size, had a minimal
FPD of merely 0.04 mg, and a FPF of 0.29% of the RD (14 mg).
These results, together with the data on the particle size and
morphology, clearly demonstrated that the use of GLY in the
formulation caused the drug particles to fuse together during
the spray-drying process, damaging the micronized struc-
ture, and hence the delivery ability of spray-dried particles to
the lungs. The HIS-AZT spray-dried powders demonstrated a
FPF of 51.4% w/w (FPD of 13.0 mg divided by RD of 23.3 mg) that
was significantly higher (one-way ANOVA, Duncan’s test,
P < 0.05) than the control powder, which was in good agree-
ment with the particle sizing data that demonstrated a
statistically smaller D [4, 3] for HIS-AZT powder (2.15 μm) in
comparison with that of AZT spray-dried powders (2.17 μm).
These results clearly show that the addition of HIS in the for-
mulation enhances the powder dispersibility.This could possible
be due to the addition of HIS in the formulation that de-
creases the cohesion and adhesion of the spray-dried powders.
This was also confirmed by the superior compressible
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Fig. 3 – Aerodynamic particle size distribution of AZT
spray-dried microparticles (35% relative humidity, 20 °C) at
60 L/min for 5 seconds. Data presented as mean ± SD, n = 3.
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attribute of HIS-AZT dry powders (ρb was only 0.49 g/cm3, while
ρt was highly increased to 0.79 g/cm3), suggesting a bigger dis-
tance between particles and subsequently having lower cohesive
forces of HIS-modified spray-dried particles. On the other hand,
the LEU-AZT spray-dried powders had FPD and RD of 12.8 mg
and 20.8 mg respectively, resulting in a high FPF of 61.7%, which
was significantly greater (one way ANOVA, Duncan’s test,
P < 0.05) than the control powders, suggesting that the major-
ity of drug particles can be delivered to the peripheral regions
of the lungs following inhalation. The significantly improved
lung deposition of LEU-modified spray-dried powders may be
related to their densities (ρb and ρt) that were less than half
of the control powders.The reduction in powder densities could
play an important role to assist the powder aerosolization, and
thereafter to improve the particle deposition in the lower stages.
The AZT, HIS-AZT and LEU-AZT spray-dried powders had
MMAD in the range of 1.71–1.89 μm (Table 3), which was smaller
than the physical diameter size of the particles, as deter-
mined by laser diffraction and confirmed by SEM visualization.
This is the reflection that the furrowed surface morphology
(AZT), decreased cohesion feature of particles (HIS-AZT, evi-
denced by high compressibility) and very low density (LEU-
AZT) resulted in improved dispersibility of particles. It has been
proven that the increase in surface roughness can improve par-
ticle flowability and dispersibility [20]. However, in previous
studies, the excipients were selected purposively to increase
the surface roughness of spray-dried particles [12,21,22]. In this
study the active pharmaceutical ingredient (AZT) itself was able
to generate the furrowed particles after spray-drying, which
did provide AZT dry powders with good aerosolization effi-
ciency.To the best of our knowledge, HIS as excipient to prepare
spray-dried powders for inhalation has not been reported before.
In this study, we have demonstrated that the addition of HIS
to the spray-drying solution can generate powders with high
condensability, through enhancing the distance between par-
ticles, leading to decreased cohesion between particles with
subsequent increased dispersibility and improved deposition
in the lungs. Furthermore, the use of LUE was shown to in-
crease the flowability, dispersibility and aerosolization
performance of drug particles for inhalation, as reported in pre-
vious studies [8,12,15,23,24]. The mechanism was probably
related to its hydrophobic feature [25] and surfactant-like facet
[26], which may facilitate the LEUmolecules drift to the droplet
surface during spray-drying and therefore modify surface
characteristics, in particular the aerosolization characteris-
tics. Moreover, this study also showed that the use of LEU at
the concentration of 60% w/w in the formulation can gener-
ate hollow spray-dried particles with significant decreased
powder densities, providing additional evidence in addition to
the surface modification to enhance flowability, dispersibility
and lung deposition of LEU-modified spray-dried powders [27].
4. Conclusion
In this study, AZT spray-dried powders were prepared for in-
halation and the influence of different amino acids used as the
excipients on the physiochemical properties and particularly
in-vitro deposition was investigated. The use of GLY in the for-
mulation resulted in the spray-dried powders fusing together
agglomerates impacting on their aerosol performance, which
was extremely poor. In comparison with AZT spray-dried
powders, HIS-AZT dry powders were more compressible, in-
dicating a bigger distance and lower cohesion between particles,
while LEU-AZT spray-dried particles had hollow particle struc-
tures that drastically decreased the formulation densities.The
changes in physiochemical properties resulted in these dry
powders having enhanced dispersibility that resulted in an im-
proved deposition to the lower respiratory tract, especially for
LEU-modified spray-dried powders.
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